BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18649362)

  • 1. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
    Müerköster SS; Werbing V; Koch D; Sipos B; Ammerpohl O; Kalthoff H; Tsao MS; Fölsch UR; Schäfer H
    Int J Cancer; 2008 Oct; 123(8):1751-60. PubMed ID: 18649362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
    Kha ML; Hesse L; Deisinger F; Sipos B; Röcken C; Arlt A; Sebens S; Helm O; Schäfer H
    Oncogene; 2019 Feb; 38(9):1461-1476. PubMed ID: 30302023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
    Lu C; Yang D; Sabbatini ME; Colby AH; Grinstaff MW; Oberlies NH; Pearce C; Liu K
    BMC Cancer; 2018 Feb; 18(1):149. PubMed ID: 29409480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta.
    Müerköster S; Wegehenkel K; Arlt A; Witt M; Sipos B; Kruse ML; Sebens T; Klöppel G; Kalthoff H; Fölsch UR; Schäfer H
    Cancer Res; 2004 Feb; 64(4):1331-7. PubMed ID: 14973050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
    Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
    Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression.
    Gao J; Wang L; Xu J; Zheng J; Man X; Wu H; Jin J; Wang K; Xiao H; Li S; Li Z
    J Exp Clin Cancer Res; 2013 Nov; 32(1):86. PubMed ID: 24423239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
    Sebens Müerköster S; Werbing V; Sipos B; Debus MA; Witt M; Grossmann M; Leisner D; Kötteritzsch J; Kappes H; Klöppel G; Altevogt P; Fölsch UR; Schäfer H
    Oncogene; 2007 Apr; 26(19):2759-68. PubMed ID: 17086212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent.
    Schäfer H; Geismann C; Heneweer C; Egberts JH; Korniienko O; Kiefel H; Moldenhauer G; Bachem MG; Kalthoff H; Altevogt P; Sebens S
    Carcinogenesis; 2012 Jan; 33(1):84-93. PubMed ID: 22095073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypomethylating therapy in an aggressive stroma-rich model of pancreatic carcinoma.
    Shakya R; Gonda T; Quante M; Salas M; Kim S; Brooks J; Hirsch S; Davies J; Cullo A; Olive K; Wang TC; Szabolcs M; Tycko B; Ludwig T
    Cancer Res; 2013 Jan; 73(2):885-96. PubMed ID: 23204224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of L1CAM in pancreatic duct cells is transforming growth factor beta1- and slug-dependent: role in malignant transformation of pancreatic cancer.
    Geismann C; Morscheck M; Koch D; Bergmann F; Ungefroren H; Arlt A; Tsao MS; Bachem MG; Altevogt P; Sipos B; Fölsch UR; Schäfer H; Müerköster SS
    Cancer Res; 2009 May; 69(10):4517-26. PubMed ID: 19435915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
    Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.